Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ebronucimab - AD Pharmaceuticals/Akeso Biopharma

Next Previous
X
Search
Drug Profile

Ebronucimab - AD Pharmaceuticals/Akeso Biopharma

Alternative Names: AK-102

Latest Information Update: 28 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Developer AD Pharmaceuticals
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type II

Most Recent Events

  • 15 Oct 2024 Akeso Biopharma plans a phase I pharmacokinetics trial (In volunteers) in China (SC, Injection) in November 2024 (NCT06641388) (CTR20243817)
  • 30 Sep 2024 Registered for Hypercholesterolaemia (Adjunctive treatment) in China (SC) - First global approval
  • 30 Sep 2024 Registered for Hyperlipidaemia (Adjunctive treatment) in China (SC) - First global approval

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top